Emma Reeve - 12 Jun 2026 Form 4 Insider Report for Whitehawk Therapeutics, Inc. (WHWK)

Reporting relationship: Director
Issuer ticker: WHWK
Reported as of: 12 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Jun 2026, 17:26:32 UTC
Prior SEC filing: 06 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Stephen Rodin, as Attorney-in-Fact

Key filing fact

Emma Reeve filed Form 4 for Whitehawk Therapeutics, Inc. (WHWK) on 15 Jun 2026.

Key facts

This page summarizes Emma Reeve's Form 4 filing for Whitehawk Therapeutics, Inc. (WHWK).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Jun 2026, 17:26.

Change

Previous filing in this sequence was filed on 06 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001680329 Primary reporting owner

Reeve Emma

Relationship: Director
Address: C/O WHITEHAWK THERAPEUTICS, INC., 2 HEADQUARTERS PLAZA, EAST BUILDING, 11T, MORRISTOWN
Signature: /s/ Stephen Rodin, as Attorney-in-Fact
Signature date: 15 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

WHWK transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +38,040
Change %
Price: $0.000000^*
Shares after: 38,040
Date: 12 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 38,040
Exercise price: $4.16
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026.